Enzymatica AB (publ) (ENZY.ST)
- Previous Close
3.1000 - Open
3.1000 - Bid 3.0000 x --
- Ask 3.1000 x --
- Day's Range
3.0000 - 3.1400 - 52 Week Range
1.3400 - 5.4500 - Volume
65,906 - Avg. Volume
202,038 - Market Cap (intraday)
728.205M - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date Jul 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company's product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
www.enzymatica.se21
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ENZY.ST
View MorePerformance Overview: ENZY.ST
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENZY.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENZY.ST
View MoreValuation Measures
Market Cap
752.48M
Enterprise Value
687.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.54
Price/Book (mrq)
4.76
Enterprise Value/Revenue
14.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-108.03%
Return on Assets (ttm)
-20.30%
Return on Equity (ttm)
-43.26%
Revenue (ttm)
48.43M
Net Income Avi to Common (ttm)
-52.32M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
66.62M
Total Debt/Equity (mrq)
1.19%
Levered Free Cash Flow (ttm)
-41.33M